Envafolimab Recruiting Phase 3 Trials for Biliary Tract Neoplasms Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03478488Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC